Synthetic Compound Inhibited Lung Cancer Cell Growth
Researchers found a new compound that suppresses pathways lung cancer cells use to survive and form new vessels.
Updated on Oct. 9, 2026 in Cancer
Scientists identified 22-benzyloxydaphlongaminone as a synthetic intermediate that interrupts the energy production of lung adenocarcinoma cells. This preliminary laboratory finding highlights a potential new way to target cancer cell metabolism.
Why it matters
Understanding how cancer cells generate energy through glycolysis could eventually help researchers disrupt the formation of vasculogenic mimicry, a process tumors use to create their own blood supply. This research identifies a specific metabolic pathway that may be vulnerable to intervention.
In an in vitro study using A549 lung adenocarcinoma cells, the compound 22-benzyloxydaphlongaminone was shown to suppress vasculogenic mimicry. The researchers observed this effect by measuring reduced levels of glycolytic enzymes and intracellular ATP, though these are preliminary findings.
The details
The compound works by interfering with glycolysis, the metabolic process by which cancer cells break down glucose for energy. By reducing the expression of key enzymes aldolase A and enolase 1, the substance starves the cells of the ATP they need to function. This inhibition of energy pathways prevents the cells from engaging in vasculogenic mimicry, a mechanism that helps tumors build vessel-like structures to support their growth.
Timeline
October 9, 2026: The research findings were published.
Health Landscape
Targeting the unique metabolic needs of cancer cells remains a significant area of focus within the broader NCI-supported study of cancer metabolism. This research adds to the growing evidence that inhibiting glycolysis may be a viable strategy for disrupting tumor-specific vessel formation.
This is a laboratory finding in a cell line and does not provide an immediate change to current lung cancer treatment or prevention strategies. Patients undergoing lung cancer treatment should continue to follow their current care plans and discuss any questions about new research with their oncologist.
The takeaway
This discovery offers a potential new target for future drug development focusing on tumor metabolism. Readers should note that findings at the cellular level require extensive further study before they can be considered for clinical use.
Further reading
Learn more about the latest research into Cancer and how emerging treatments are being evaluated.
Source note: This article includes information reported by Nature.
